Program
VH4367310
A development code.
In GlaxoSmithKline's pipeline, HIV integrase inhibitor
. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.
Furthest: phase 1, since Sep 8, 20261 company-led study, 1 open or runningNext primary completion: Dec 26, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 11 open or running | phase 1since Sep 8, 2026 | Sep 8, 2026 | Dec 26, 2028phase 1 · NCT07818915 |
- Named in GlaxoSmithKline’s own pipeline as
VH4367310
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2026First study: phase 1 study in HIV InfectionsFirst studyNCT07818915 · 112 planned · United States
Ahead
- Dec 26, 2028Primary completion: phase 1 study in HIV InfectionsNCT07818915
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HIV integrase inhibitor”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07818915HIV Infections · United States | 1 | Recruiting | Dec 26, 2028 | 112 |
How it is read
Names in the registry
- “VH4367310”, 1 entry
Codes read as this program: VH4367310.
Conditions, from the studies’ own filings
- HIV Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.